Check back in for all the latest news from Anagram Therapeutics.
Find recent and archived press releases for Anagram Therapeutics. Explore the latest news and stay up to date on Anagram.
- Anagram Therapeutics Expands Leadership Team to Accelerate Development of ANG003 and Pipeline of Orally Delivered Enzyme Therapies for Rare DiseasesMarch 06, 2026
- Anagram Therapeutics Presents Positive Data from Clinical Study in People with Cystic Fibrosis (CF) Related Exocrine Pancreatic Insufficiency at North American CF ConferenceSeptember 27, 2024
- Anagram Therapeutics Completes Dosing Study of ANG003, a Broad-Spectrum Oral Enzyme Replacement Therapy, in People with Cystic FibrosisJuly 30, 2024
- Anagram Therapeutics Announces Initiation of Clinical Study of ANG003 in People with Cystic FibrosisSeptember 27, 2023
- Anagram Therapeutics Appoints Three Industry Veterans to Leadership Team, Focused on Accelerating the Company’s Pipeline of Orally Delivered Enzymes for Rare DiseasesApril 20, 2023
- Anagram Therapeutics Launches to Advance Orally Delivered Enzymes to Treat Malabsorption Syndromes and Nutrient Metabolism DisordersApril 04, 2023